



*JPW*

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 99-383-B1)

In re Application of:

John W. Belmont et al.

Serial No.: 10/803,738

Filing Date: March 18, 2004

For: Phosphatases Which Activate Map  
Kinase Pathways

Examiner: Unassigned

Group Art Unit: 1651

Confirmation No.: 8046

**TRANSMITTAL LETTER**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:
  - a) Second Supplemental Information Disclosure Statement;
  - b) U.S. PTO 1449 Form with copy of reference; and
  - c) Postcard.
2. With respect to fees:
  - a) No fee is required.
  - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 6 day of October, 2005.

Respectfully submitted,

Date:

Oct. 6, 2005

*Emily Miao*  
\_\_\_\_\_  
Emily Miao  
Registration No. 35,285



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 99-383-B1)

In re Application of:	)	
	)	
John W. Belmont et al.	)	Examiner: Unassigned
	)	
Serial No.: 10/803,738	)	
	)	Group Art Unit: 1651
Filing Date: March 18, 2004	)	
	)	
For: Phosphatases Which Activate Map	)	Confirmation No.: 8046
Kinase Pathways	)	

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In order to comply with discretionary regulations 37 CFR §§1.97 and 1.98, attached hereto is Form PTO-1449, copies<sup>1</sup> of the documents listed thereon. These documents contain information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a

---

<sup>1</sup>To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the file of a parent application. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited, then none is known to undersigned.


rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider any of the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Dated: Oct. 6, 2005

Respectfully submitted,



Emily Miao  
Registration No. 35,285

McDonnell Boehnen Hulbert & Berghoff LLP  
300 South Wacker Drive  
Chicago, Illinois 60606  
Telephone : (312) 913-0001  
Facsimile: (312) 913-0002



FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

99,383-B1

Serial No.

10/803,738

**SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**

John W. Belmont et al.

**Filing Date:**

March 18, 2004

**Group:**

8046

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1	5,459,036	10/17/95	Lechner, et al. (Abstract)			
	2	5,663,314	09/02/97	Seeger, et al., (Abstract)			

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation Yes	No

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

	3	Blackshear, et al., "Brca1 and Brca2 expression patterns in mitotic and meiotic cells of mice," <i>Oncogene</i> , Vol. 16, pp. 61-68 (1998), U.S.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.